What year does the tirzepatide patent expire?
Tirzepatide (Mounjaro/Zepbound) is protected by a mix of patent rights and regulatory exclusivity, so there isn’t a single “one-year” answer for every jurisdiction and asset. The most widely cited U.S. patent-exclusivity timelines for tirzepatide indicate expiry in the early-to-mid 2030s, with some protections extending to 2037 depending on the specific patent and exclusivity package.[1]
When could generic or biosimilar versions realistically arrive?
Even if a particular patent expires, generic entry typically depends on whether other patents still block the drug product in that market, plus timing rules for exclusivity and any litigation outcomes. For tirzepatide, that means generic competition in the U.S. is generally expected not in the near term, but later in the 2030s, after the later-blocking patents/exclusivity end.[1]
Why does the “expiry year” vary by source?
Different sources may reference different layers of protection, such as:
- specific composition-of-matter or method patents (each with its own expiration date),
- formulation or device-related patents,
- and regulatory exclusivity terms that can extend beyond the earliest patent expiry.[1]
Where can I check the exact patent and expiration date?
You can review specific tirzepatide patent listings and associated expiry information via DrugPatentWatch.com, which tracks patent estate timelines for drugs like tirzepatide.[1]
Sources:
[1] https://www.drugpatentwatch.com/p/tirzepatide/